Actionable news
0
All posts from Actionable news
Actionable news in TROV: TrovaGene, Inc.,

Clinical Data Featuring Trovagene'S Precision Cancer Monitoring Platform To Be Presented At The Molecular Dx Europe Conference

The following excerpt is from the company's SEC filing.

Urinary liquid biopsy shown to monitor early drug response to anti-EGFR therapy

SAN DIEGO, April 7, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring® platform will be presented at the Molecular DX Europe conference. Hatim Husain, M.D., University of California, San Diego Moores Cancer Center will deliver the presentation at 11:15 a.m. (WEST) in Lisbon, Portugal. The presentation, entitled

Dynamic Changes in EGFR Mutation Circulating Tumor DNA in Urine on Anti-EGFR Therapy

will feature data from clinical studies in lung cancer.

Molecular DX Europe Presentation Details

Circulating Cell-Free DNA session: strategies for bringing liquid biopsy to the clinic.

Title: Dynamic Changes in EGFR Mutation Circulating Tumor DNA in Urine on Anti-EGFR Therapy

Presenter: Hatim Husain, M.D., University of California, San Diego Moores Cancer Center.

Presentation Highlights:

Monitoring early drug response to anti-

therapy to model tumor lysis

Analyzing pretreatment kinetics and dynamic changes in circulating tumor DNA (ctDNA) for patients on therapies directed against

Evaluating urine as a modality for monitoring ctDNA.

Trovagene's urine-based

oncogene mutation assays are now available to healthcare providers for detection and or monitoring of tumor dynamics in their patients before, during and after treatment...


More